Lupin Receives USFDA Approval for Generic Pirfenidone Tablets Used in Lung Disease Treatment

28 Aug 2023 , 01:41 PM

Lupin has been granted approval by the USFDA to market Pirfenidone tablets in 267 mg and 801 mg strengths. Pirfenidone is used for treating idiopathic pulmonary fibrosis. The product is the generic version of La Roche Inc’s Esbriet tablets.

The estimated annual sales of Pirfenidone tablets in the US were around USD 218 million, according to IQVIA MAT data.

For feedback and suggestions, write to us at [e-mail]